Witty was the top executive of the country's largest healthcare company during some of its darkest chapters, including the killing of the head of its health insurance business.

Their concerns come in response to the bill unveiled Sunday night by House Republicans that would tighten eligibility rules, create work requirements and freeze provider taxes under Medicaid—the federal-state program that insures nearly 80 million low-income Americans.

Industry leaders and policy experts have said President Trump’s executive order on Most Favored Drug Pricing is flawed and ignores the basic economics of the global drug marketplace.

The House Energy and Commerce Committee has scheduled a public markup hearing for the Republican bill for tomorrow at 2 p.m.

In a press conference, President Donald J. Trump announced that he would sign an executive order that ties drug pricing to prices in other developed countries. He also vowed to cut out the “middlemen” to bring the new prices to American citizens.

Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration beyond academic medical centers into community and outpatient settings closer to patients' homes.

A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.

Here’s what you missed this week on Managed Healthcare Executive.

The research is noteworthy given a Supreme Court decision that could result in many dialysis patients switching from commercial insurance plans to Medicare.

Specialty drugs are increasingly entering general medicine. Experts at Asembia’s AXS Summit say the trend will put a premium on leveraging artificial intelligence, technology and cross-functional expertise to create more personalized, efficient patient support services.

While providers do bring up menopause with patients during visits, there are still some knowledge gaps, according to the results of a recent survey of women ages 40 to 70 and healthcare providers.

Integrated delivery networks may be crucial to meeting the challenges posed by the complexities of specialty pharmacy.

It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.

In a conversation with Managed Healthcare Executive, 10XBeta CEO Marcel Botha warned that proposed Medicaid cuts, combined with federal budget reductions under the DOGE initiative, could exacerbate the rural healthcare crisis—threatening efforts to bring mobile, community-driven innovations to underserved areas.

Kaminski and his colleagues were pioneers in applying high-throughput, genome-scale transcript profiling to advanced lung disease.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started immunotherapy. This may be one reason why these patients responded better to certain immunotherapy treatments, researchers said.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.

As ubiquitous as lab testing is in healthcare, health plans still often overlook its importance to healthcare quality and cost containment.

Capricor officials said the company was prepared for the meeting and does not expect it to delay the FDA’s decision on the therapy.

An overview of endometriosis subtypes, treatment options and costs, according to a recent research review published in JAMA.

Payers may be tempted by lower prices and no rebates, but two-thirds of the respondents said their plan has experienced an increase in the amount of rebates they have received.

A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.